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Abstract
Rationale—The ventral tegmental area (VTA) mediates the local stimulating effects of ethanol 
(EtOH) in a region-dependent manner, with EtOH administration in the posterior but not anterior 
VTA stimulating the mesolimbic system. The serotonin-3 (5-HT3) receptor has been involved in 
the effects of EtOH on the mesolimbic system.
Objectives—The current study tested the hypothesis that EtOH would stimulate mesopallidal 
and mesocortical dopamine neurons in the posterior but not anterior VTA and that the stimulating 
effects of EtOH in the VTA would involve activation of local 5-HT3 receptors.
Methods—Wistar female rats were surgically implanted with two cannulae, one in one subregion 
of the VTA for microinjection and the other in the ventral pallidum (VP) or medial prefrontal 
cortex (mPFC) for microdialysis. Artificial CSF or EtOH (200 mg%; 44 mM) was microinjected 
in the anterior or posterior VTA, and extracellular dopamine was measured in the VP or mPFC 
with microdialysis-HPLC.
Results—EtOH injections in the posterior, but not anterior VTA, significantly increased 
extracellular dopamine levels in the VP and mPFC. Co-injections of the 5-HT3 receptor antagonist 
ICS-205,930 with EtOH in the posterior VTA significantly reduced the effects of EtOH on 
extracellular dopamine levels in the VP and mPFC.
Conclusions—The results indicate that posterior VTA dopamine neurons projecting to the VP 
and mPFC are stimulated by local administration of EtOH and that the local stimulating effects of 
EtOH are mediated, at least in part, by 5-HT3 receptors.
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Introduction
Dopamine (DA) neurons in the ventral tegmental area (VTA) and their projections to the 
forebrain cortico-limbic regions have been implicated in mediating the effects of drugs of 
abuse, including ethanol (EtOH) (Koob and Volkow 2010; McBride et al. 1999). Systemic 
administration of EtOH activates the mesolimbic DA system and increases extracellular DA 
levels in the nucleus accumbens (NAc) (Imperato and Di Chiara 1986; Weiss et al. 1993). 
This effect of EtOH is thought to be largely due to EtOH actions in the VTA. This notion is 
supported by several lines of studies. Electrophysiological studies showed that both systemic 
and local administration of EtOH stimulated VTA DA neurons (Brodie et al. 1990, 1999; 
Foddai et al. 2004; Gessa et al. 1985). In addition, intra-VTA microinjections of EtOH 
increased DA release in the NAc (Ding et al. 2009b). Furthermore, the stimulating effects of 
EtOH were demonstrated only in the posterior VTA (pVTA), but not the anterior VTA 
(aVTA), suggesting a regional difference in the action of EtOH (Ding et al. 2009b). This 
finding is consistent with behavioral studies that EtOH was reinforcing in the pVTA, but not 
aVTA (Rodd-Henricks et al. 2000; Rodd et al. 2004). Overall, the current evidence suggests 
that EtOH can stimulate pVTA DA neurons projecting to the NAc.
VTA DA neurons also project to the ventral pallidum (VP) and medial prefrontal cortex 
(mPFC) (Oades and Halliday 1987). These two regions, along with the VTA and NAc, form 
a complex circuit involved in mediating the rewarding and reinforcing effects of EtOH 
(Koob and Volkow 2010). However, the stimulating effects of EtOH on the mesopallidal 
and mesocortical systems have not been fully explored. Previous studies showed that 
systemic administration of EtOH increased extracellular DA levels in the VP (Melendez et 
al. 2003, 2004). No study thus far has examined whether this effect is due to the activation 
of mesopallidal DA neurons in the VTA, and/or is due to EtOH effects on DA terminals in 
the VP. On the other hand, the effects of systemic EtOH on the mesocortical DA system are 
not so evident. Several studies indicated that intraperitoneal (i.p.) injection of EtOH did not 
alter extracellular DA levels in the mPFC (Engleman et al. 2006; Hegarty and Vogel 1993). 
However, a number of studies have linked the mPFC DA transmission in mediating the 
effects of ethanol. For example, pharmacological manipulations of DA receptor function in 
the mPFC or 6-hydroxydopamine lesion of the mPFC altered voluntary ethanol consumption 
(Nielsen et al. 1999) or operant responding for EtOH in rats (Hodge et al. 1996; Samson and 
Chappell 2003). In addition, the alcohol-preferring P rat has lower basal extracellular DA 
concentrations in the mPFC compared to the Wistar rat, suggesting lower DA transmission 
in the mPFC may be associated with alcohol preference and drinking (Engleman et al. 
2006). Given these results, further studies are warranted to explore the neurochemical 
effects of EtOH on the mesocortical DA system.
In the present study, effects of EtOH on extracellular DA levels in the mPFC and VP were 
examined with local application of EtOH in the VTA. Given the stimulating effects of EtOH 
on mesolimbic DA neurons, we hypothesize that EtOH would activate VTA DA neurons 
projecting to the VP and mPFC and the effects would be evident in the pVTA but not aVTA.
The reinforcing and stimulating effects of EtOH appear to involve the 5-HT3 receptor. 
Systemic administration of 5-HT3 receptor antagonists suppressed voluntary EtOH 
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consumption in rats under 24-hr free-choice conditions (Knapp and Pohorecky 1992; 
McKinzie et al. 1998). Co-infusion of 5-HT3 receptor antagonists with EtOH attenuated 
EtOH self-infusions in the pVTA (Rodd-Henricks et al. 2003). Furthermore, both systemic 
and local application of the 5-HT3 receptor antagonist ICS-205,930 attenuated the systemic 
EtOH-induced increase of extracellular DA levels within the mesolimbic system (Campbell 
et al. 1996; Campbell and McBride 1995; Wozniak et al. 1990). However, no study has 
examined the involvement of 5-HT3 receptors in the local stimulating effects of EtOH on 
DA neurons in the VTA. Therefore, we hypothesize that the local stimulating effects of 
EtOH on DA neurons in the pVTA would involve the activation of 5-HT3 receptors.
Methods and Materials
Subjects
Adult female Wistar rats (250 to 320 g, Harlan, Indianapolis IN, USA) were housed in a 
temperature- and humidity-controlled room maintained on a reversed 12-hr light-dark cycle 
(light off at 9:00 am). Rats were housed in pairs upon arrival and individually after the 
surgery. Food and water were freely available except in the testing chambers. Female rats 
were used because they maintain their head size better than male rats for more accurate 
stereotaxic placements (Ding et al. 2009b; Ikemoto et al. 1997a; Rodd-Henricks et al. 2000). 
Although the estrous cycle was not monitored, counterbalanced experiments were conducted 
on different days so that any effect of a given phase of the estrous cycle was distributed 
across experiments. Protocols were approved by the Institutional Animal Care and Use 
Committee of Indiana University School of Medicine and were in accordance with 
principles in the Guide for the Care and Use of Laboratory Animals (National Research 
Council 1996).
Chemical agents
KCl, CaCl2, MgSO4 and NaC2H3O2 were purchased from Fisher Scientific (Fair Lawn, NJ, 
USA). NaCl, Na2HPO4·7H2O, MgCl2, d-glucose, sodium octyl-sulfate (SOS), 
ethylenediaminetetraacetic acid (EDTA), acetonitrile, ascorbate and the 5-HT3 receptor 
antagonist tropisetron monohydrochloride (ICS-205,930) were purchased from Sigma (St. 
Louis, MO, USA). KH2PO4 and NaHCO3 were purchased from Acros Organics (NJ, USA). 
EtOH (190 proof) was obtained from McCormick Distilling, Weston, MO.
Surgery and probe insertion procedures
Guide cannulae were implanted in the ipsilateral side of the brain as previously described 
(Ding et al. 2009b). The target regions were: aVTA (AP − 4.8 mm, ML + 2.1 mm, DV − 9.0 
mm); pVTA (AP − 5.6 mm, ML + 2.1 mm, DV − 9.0 mm); VP (AP + 0.1 mm, ML + 2.3 
mm, DV − 9.0 mm); and mPFC (AP + 3.0 mm, ML +0.7 mm, DV − 5.0 mm) (Paxinos and 
Watson 1998). Cannulae were inserted into the VTA with a 10° angle to vertical and into the 
VP or mPFC with no angle. Probes (Inner Diameter: 200 μm, Molecular Weight Cut Off: 
13,000, Spectrum Laboratories, Inc, Rancho Dominguez, CA) were inserted into the VP 
(1.5-mm active membrane) or mPFC (2.0-mm active membrane) as described previously 
(Ding et al. 2009b).
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Microinjection procedure
EtOH and ICS-205, 930 were dissolved in artificial cerebrospinal fluid (aCSF) to the desired 
concentrations prior to use. Microinjections were conducted with an electrolytic micro-
infusion transducer (EMIT) system, following the procedure described previously (Ding et 
al. 2009b). Briefly, the EMIT system was calibrated to inject a 100-nl solution in 5 seconds; 
a 15-sec timeout period followed each 5-sec injection. The injection-timeout cycle was 
repeated thirty times over a 10-min period. After the injection, the injector remained in place 
for one minute before being removed.
Microdialysis procedure
Microdialysis was conducted following procedures described previously (Ding et al. 2009b). 
Briefly, microdialysis started 16–18 hr after the probe insertion. Rats were placed into 
microdialysis chambers and connected to a Harvard pump. Microdialysis started with a 90-
min washout period with the perfusion of aCSF through probes at a rate of 1.0 μl/min. After 
the washout period, four to five baseline samples were collected, which was followed by 
microinjections of either vehicle or the drug for 10 min in the sub-region of the VTA. Five 
samples were collected thereafter. Samples were collected at 10-min intervals.
Sample analysis
DA was analyzed with a reversed-phase high performance liquid chromatography coupled 
with electrochemical detection, as described previously (Thielen et al. 2004). Briefly, 5-ul 
samples were delivered onto an analytical column (BDS Hypersil C18, 3 μm, 100 mm × 1 
mm, Thermo) with a mobile phase containing 77.0 mM NaC2H3O2, 0.5 mM EDTA, 3.4 mM 
SOS, 9.9 mM NaCl, and 6.0% acetonitrile, pH 4.0. DA was detected with a glassy-carbon 
electrode and an amperometric detector with the oxidation potential set at + 450 mV and 
sensitivity set at 1 nA/V. The signal then was analyzed with a ChromPerfect data station. 
The detection limit for DA was approximately 100 pmol/l with a signal-to-noise ratio of 3:1.
The effects of EtOH in different sub-regions of the VTA on extracellular DA levels in the VP
Rats were randomly assigned to the following groups (n = 5–8/group). Two groups received 
either aCSF or EtOH (200 mg%; 44 mM) in the aVTA; and the other two groups received 
either aCSF or 200 mg% EtOH in the pVTA. Extracellular DA was sampled in the VP. For 
female Wistar rats, the 200 mg% EtOH (44 mM) appeared to be an optimal concentration to 
be self-infused into the p-VTA (Rodd-Henricks et al. 2000) and to increase DA release in 
the NAc after being injected into the pVTA (Ding et al. 2009b).
The second experiment examined the involvement of the 5-HT3 receptor in the effects of 
EtOH in the pVTA where local administration of EtOH increased extracellular DA levels in 
the VP. Two groups of rats received co-infusion of the 5-HT3 receptor antagonist 
ICS-205,930 (100 or 200 μM, n = 5–8 per dose) and 200 mg% EtOH in the pVTA during 
the microdialysis. ICS-205,930 (100 μM) has been shown to attenuate self-infusion of EtOH 
into the pVTA (Rodd-Henricks et al. 2003). A third group received microinjections of the 
antagonist alone (200 μM, n = 5) in the pVTA. To reduce the number of rats, groups 
receiving either EtOH (200 mg%) or aCSF alone in the pVTA were not repeated in this 
experiment because the first experiment outlined above already contained these groups. 
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However, results from the first experiment were adopted for statistical analysis in this 
experiment.
The effects of EtOH in different sub-regions of the VTA on extracellular DA levels in the 
mPFC
Rats were randomly assigned to the following groups (n = 5–8/group). Two groups received 
microinjections of either aCSF or 200 mg% EtOH in the aVTA; and the other two groups 
received microinjections of either aCSF or 200 mg% EtOH in the pVTA. Extracellular DA 
levels in the mPFC were measured.
In the pVTA, where local administration of EtOH increased extracellular DA levels in the 
mPFC, the effects of co-infusion of the 5-HT3 receptor antagonist ICS-205,930 with 200 mg
% EtOH were examined, following the same procedure described above in experiment# 2 in 
the study performed above.
Histology
At the end of experiments, rats were euthanized and bromophenol blue (1%) was delivered 
into the target regions. Brains were removed and sections (40 μm) were prepared and 
stained, as described previously (Ding et al. 2009b). The placement of injection sites and 
probes were determined in accordance with the rat brain atlas of Paxinos & Watson (1998).
Statistical analysis
DA levels were expressed as percent of baseline averaged from the last three baseline 
samples prior to the microinjection. Analyses of variance (ANOVA) with repeated measures 
were conducted to analyze the time-course data. Area under the curve (AUC) coupled with 
one-way ANOVA were used to analyze data from the ICS-205,930 co-infusion experiments. 
The AUC values were derived from time-course data of percentage DA levels. The 
calculation included all time points and used 100% as baseline. Significant difference was 
set at p < 0.05. Post-hoc tukey’s b tests were performed following significant major effects.
Results
Histology
Figure 1 shows placements of probes in the mPFC and VP. In the mPFC, probes were 
mainly in the prelimbic and infralimbic areas of the mPFC. Some probes also covered a 
small portion of the anterior cingulate. In the VP, probes were mainly in the VP area 
underneath the anterior commissure. Some probes also covered a small portion of the lateral 
globus pallidus to the dorsal side and a small portion of the nucleus of horizontal limb of the 
diagonal band (HDB) or the magnocellular preoptic nucleus (MCPO) to the ventral side. To 
be included in the analysis, rats had to have at least 75% of the probe in the VP or mPFC.
Figure 2 shows the placement of micro-injection sites within the aVTA and pVTA. Previous 
studies indicated that the aVTA ranges from coronal section 4.8 to 5.2 mm posterior to 
bregma, and the pVTA ranges from coronal section 5.3 to 6.3 mm posterior to bregma (Fig. 
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2) (Ding et al. 2009b; Rodd-Henricks et al. 2000). Approximately 80% of the rats fulfilled 
these criteria. Rats with injection sites outside of the VTA were not included in analysis.
Effects on extracellular DA levels in the VP
Figure 3 shows time-course effects of microinjections of aCSF or EtOH (200mg%; 44 mM) 
in different sub-regions of the VTA on extracellular DA levels in the VP. The average basal 
extracellular DA levels in each group were shown in Table 1. Mixed repeated-measures 
ANOVA with ‘time’ as within factor and ‘region’ and ‘treatment’ as between factors 
revealed significant ‘time’ x ‘region’ x ‘treatment’ interaction (F5, 11 = 3.78, p = 0.031). The 
significant interaction term allowed further analyses to be conducted in each individual sub-
region of the VTA. In the pVTA, significant effects of ‘time’, ‘treatment’ and ‘time’ x 
‘treatment’ interaction were found (all F values > 3.87, all p values < 0.05). Microinjections 
of 200 mg% EtOH in the pVTA significantly increased extracellular DA levels in the VP to 
approximately 160% of baseline levels, whereas microinjections of aCSF had no effect on 
extracellular DA levels (Fig. 3A). In the aVTA, there was no significant effect of ‘time’, 
‘treatment’ or ‘time’ x ‘treatment’ interaction (all F values < 0.41, all p values > 0.5). 
Microinjections of neither 200 mg% EtOH nor aCSF in the aVTA significantly altered 
extracellular DA levels in the VP (Fig. 3B). Furthermore, EtOH produced a significantly 
greater effect in the pVTA than aVTA (F1, 8 = 6.43, p = 0.035).
Figure 4 shows the effects of co-injections of the 5HT3 receptor antagonist ICS-205,930 
(100 or 200 μM) with EtOH in the pVTA. The basal DA levels in each group were shown in 
Table 1. AUC values were calculated from each group and were analyzed with one-way 
ANOVA (Fig. 4). The analysis indicated a significant effect of treatment (F4, 23 = 6.10, p = 
0.002). Post-hoc analysis indicated that ICS-205,930 significantly reduced the effect of 200 
mg% EtOH in a concentration-dependent manner (p < 0.05). In addition, 200 μM 
ICS-205,930 alone did not significantly alter extracellular DA levels in the VP.
Effects on extracellular DA levels in the mPFC
Figure 5 shows the time-course effects of microinjections of aCSF or 200 mg% EtOH into 
different sub-regions of the VTA on extracellular DA levels in the mPFC. Basal 
extracellular DA levels in each group were shown in Table 1. Mixed repeated-measures 
ANOVA with ‘time’ as within factor and ‘region’ and ‘treatment’ as between factors 
revealed a significant ‘time’ x ‘region’ x ‘treatment’ interaction (F7,16 = 3.07, p = 0.03). 
Further statistical analyses followed the same procedure as outlined above for data shown in 
Fig. 3. Microinjections of 200 mg% EtOH into the pVTA significantly increased 
extracellular DA levels in the mPFC to approximately 150% of baseline levels (F1, 12 = 
10.14, p < 0.05); microinjections of aCSF, on the other hand, had no effect (Fig. 5A). In the 
aVTA, however, neither aCSF nor 200 mg% EtOH significantly altered mPFC DA levels 
(all F values <1.98, all p values > 0.05, Fig. 5B). Similarly, EtOH produced greater effects 
in the pVTA compared to the aVTA (F1, 13 = 14.98, p = 0.002).
Figure 6 shows the effects of co-injection of the 5HT3 receptor antagonist ICS-205,930 (100 
or 200 μM) on the actions of EtOH in the pVTA. The basal DA levels in each group were 
shown in Table 1. AUC analysis indicated a significant effect of treatment (Fig. 6, F4, 25 = 
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4.35, p = 0.008). Post-hoc analysis indicated that ICS-205,930, at both 100 and 200 μM 
concentrations, produced similar reduction on EtOH-induced DA increase in the mPFC (p < 
0.05). In addition, microinjections of 200 μM ICS-205,930 alone did not significantly alter 
extracellular DA levels in the mPFC.
Since ICS-205,930 also interacts with the GABAA receptor at high micro-molar ranges 
(Klein et al. 1994), a separate preliminary experiment was carried out to assess the 
involvement of GABAA receptors in the local reinforcing actions of EtOH on DA neurons 
within the pVTA. In a intracranial self-administration paradigm (Ding et al. 2009c; Rodd-
Henricks et al. 2000), Wistar rats readily responded for the self-infusion of 200 mg% EtOH 
alone into the pVTA and discriminated the active from the inactive lever (Fig. 7, Rodd-
Henricks et al. 2000, 2003). Co-administration of 250 μM bicuculline, a GABAA receptor 
antagonist, with 200 mg% EtOH did not significantly alter responding on the EtOH lever 
(Fig. 7), suggesting that activation of GABAA receptors are not involved in the local 
stimulating effects of EtOH within the pVTA.
Discussion
The current study demonstrated that local administration of EtOH into the pVTA but not 
aVTA increased DA release in both the VP and mPFC (Figs. 3 & 5), and that co-injections 
of the 5-HT3 receptor antagonist ICS-205,030 attenuated the local stimulating effects of 
EtOH on pVTA DA neurons projecting to the VP and mPFC (Figs. 4 and 6). These results 
suggest that DA neurons in the pVTA, but not the aVTA, are stimulated by EtOH and the 
stimulating effects of EtOH are mediated, at least in part, by activation of local 5-HT3 
receptors.
Local application of 200 mg% EtOH in the pVTA significantly increased extracellular DA 
levels in the VP to approximately 160% of baseline (Fig. 3), indicating EtOH stimulation of 
mesopallidal DA neurons in the pVTA. These findings suggest that local stimulation of 
pVTA mesopallidal DA neurons may underlie the neurochemical effects of systemically 
administered EtOH on the mesopallidal DA system (Melendez et al. 2003, 2004). However, 
the results of the present study do not eliminate the possibility that systemic EtOH could 
also have an effect directly within the VP. The elevation of extracellular DA levels in the VP 
may be involved in some important functions, such as locomotor activation (Klitenick et al. 
1992). Two studies have also linked VP DA to EtOH self-administration in alcohol-
preferring P rats (Melendez et al. 2004, 2005).
Direct application of EtOH into the pVTA also stimulates mesocortical DA neurons, as 
indicated by elevated DA release in the mPFC (Fig. 5). These findings are in contrast to 
previous reports that systemic administration of EtOH did not alter extracellular levels of 
DA in the mPFC (Engleman et al. 2006; Hegarty and Vogel 1993). Reasons for this apparent 
disagreement between the i.p. injection and microinjection studies may be due to local 
administration of ethanol only acting on DA cell bodies within the VTA, whereas systemic 
administration of ethanol acts not only on the cell bodies in the VTA, but also in terminal 
areas within the mPFC. It is possible that systemically-administered EtOH may produce 
certain inhibitory effects on DA terminals within the mPFC, which overrides the stimulatory 
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effects of ethanol in the cell body area. In the mPFC, there appears to be tonic GABA-
mediated inhibition of DA release (Santiago et al. 1993). EtOH has been shown to increase 
both GABAA and GABAB receptor-mediated inhibition (Allan et al. 1987; Federici et al. 
2009). Therefore, a tentative hypothesis can be proposed that EtOH in the mPFC could 
inhibit DA release locally by enhancing GABAergic inhibition, which could counteract the 
stimulating effects of EtOH in the VTA. Another possibility to explain why systemic EtOH 
did not alter mPFC DA levels may be due to EtOH activating inhibitory projections from 
other brain regions to the mPFC, which inhibits DA release within the mPFC. Further 
studies will be needed to test these possibilities.
The current study suggested that activation of local 5-HT3 receptors may be involved in the 
stimulating effects of EtOH on DA neurons in the pVTA, as demonstrated by the findings 
that co-infusion of the 5-HT3 receptor antagonist ICS-205,930 significantly attenuated 
EtOH-induced DA release in the VP and mPFC (Figs. 4 & 6). These findings are consistent 
with findings showing co-infusion of 5-HT3 receptor antagonists inhibit the local reinforcing 
actions of EtOH in the pVTA (Rodd-Henricks et al. 2003), as well as findings demonstrating 
that local perfusion of ICS-205,930 attenuated systemic EtOH-induced DA increase in both 
the VTA and NAc (Campbell et al. 1996; Campbell and McBride 1995).
Activation of 5-HT3 receptors within the pVTA can increase DA neuronal activity and 
produce reinforcing effects. The 5-HT3 receptor agonist, 1-(m-chlorophenyl)-biguanide 
(CPBG), can be self-administered into the pVTA (Rodd et al. 2007) and increase local 
extracellular DA levels (Campbell et al. 1996; Liu et al. 2006). Furthermore, EtOH can 
increase the 5-HT3 receptor-mediated current in vitro (Lovinger and White 1991; Machu 
and Harris 1994) and local application of CPBG can enhance the systemic EtOH-induced 
increase of extracellular DA levels in the VTA (Campbell et al. 1996). Therefore, research 
with both 5-HT3 agonists and antagonists discussed above suggests that EtOH can stimulate 
DA neurons in the pVTA via enhancing the activity of 5-HT3 receptors and that the 
inhibition of 5-HT3 receptors would attenuate the stimulating effects of EtOH.
Low to moderate densities of 5-HT3 receptor binding sites were detected in the VTA with 
receptor autoradiography (Ge et al. 1997). Although the cellular localization of 5-HT3 
receptors is not known, the VTA DA neuron is a strong candidate because of the 
demonstrated synaptic connectivity of 5-HT terminals on VTA DA neurons (Van Bockstaele 
et al. 1994). The 5-HT3 receptors on DA neurons could be involved in the effects of EtOH, 
as activation of these 5-HT3 receptors would directly stimulate DA neurons. However, 5-
HT3 receptors on GABA inter-neurons and/or GABA terminals may not be involved in the 
EtOH effect, as activation of these receptors would increase GABA release onto DA 
neurons.
At micro-molar concentrations, ICS-205,930 has been shown to inhibit the GABAA 
receptor-mediated inhibition (Klein et al. 1994). Therefore, it is possible that ICS-205,930 
could be acting at GABAA receptors to produce its inhibitory effects on EtOH stimulated 
DA release. GABAA receptors form different circuits in regulating DA neuron activity 
within different sub-regions of the VTA (Arnt and Scheel-Kruger 1979; Ding et al. 2009a; 
Ikemoto et al. 1997b; 1998), with little tonic GABAA receptor-mediated inhibition in the 
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pVTA. A preliminary study ( Fig. 7) was conducted to examine the effects of a GABAA 
antagonist on the reinforcing stimulating effects of EtOH on DA neurons in the pVTA. The 
results of this study indicated that bicuculline had no effect on the self-infusion of EtOH in 
the pVTA, suggesting that the reinforcing stimulating effects of EtOH within the pVTA are 
not mediated via activation of local GABAA receptors. These latter results support the idea 
that the effects of ICS-205,930 observed in the present study may be occuring through 
inhibition of 5-HT3 receptors. This conclusion is consistent with a previous study (Rodd-
Henricks et al. 2003) indicating that zacropride, another 5-HT3 receptor antagonist without 
an interaction at the GABAA receptor (Smith et al. 1988), was more potent than 
ICS-205,930 in inhibiting EtOH self-administration in the pVTA, suggesting that inhibition 
of local 5-HT3 receptors alone was sufficient to prevent the stimulating actions of EtOH 
within the pVTA.
In addition, ICS-205,930 functions as a partial agonist at the α7 nicotinic receptor (Macor et 
al. 2001). In the VTA, these receptors are located pre-synaptically on glutamatergic 
terminals (Jones and Wonnacott 2004) and are involved in the stimulation of DA neurons 
(Schilstrom et al. 1998). However, several lines of evidence suggest these receptors may not 
be involved in the effects of ICS-205,930 observed in the present study (Figs. 4 & 6). First, 
α7 nicotinic receptors may not mediate the stimulating effects of EtOH as demonstrated by 
findings that EtOH can inhibit the activity of the α7 nicotinic receptor (Narahashi et al. 
1999). Second, the findings that microinjection of 200 μM ICS-205,930 alone did not 
significantly alter extracellular DA levels in the VP and mPFC suggest that the action of 
ICS-205,930 on α7 nicotinic receptors did not produce general inhibition of DA neurons. 
Therefore, the effects of ICS-205,930 observed in the present study are not likely due to an 
action on local α7 nicotinic receptors.
The stimulating effects of EtOH within the VTA appear to be sub-region dependent. Local 
application of 200 mg% (44 mM) EtOH in the pVTA, but not aVTA, induced a comparable 
increase (50–60 %) of extracellular DA levels in the NAC, VP and mPFC (Figs. 3 & 5) 
(Ding et al. 2009b). These findings are consistent with behavioral studies demonstrating that 
EtOH is reinforcing in the pVTA but not aVTA (Rodd-Henricks et al. 2000), and suggest 
that activation of mesopallidal and mesocortical systems, in addition to the mesolimbic 
system, may contribute to the reinforcing properties of EtOH in the pVTA. Together, these 
studies suggest that the pVTA is more sensitive than the aVTA to the stimulating effects of 
EtOH. The mechanisms for this difference are unknown. One possibility may be related to 
possible differential projections to the target regions from the two VTA sub-regions. 
However, neuro-anatomical evidence does not support this idea because both the aVTA and 
pVTA appear to project to the VP and mPFC (Klitenick et al. 1992; Swanson 1982). 
Another possibility may be differences in receptors and/or neuronal circuits between the two 
subregions, e.g. 5-HT3 receptors. The pVTA appeared to be more sensitive to 5-HT3 
receptor activation than the aVTA (Liu et al. 2006; Rodd et al. 2007), which may contribute 
to the differential effects of EtOH between the two sub-regions of the VTA. The differential 
functions of 5-HT3 receptors may be due to differential expression of 5-HT3 receptors 
between the aVTA and pVTA; however, further neuro-anatomical studies need to be 
conducted to test this hypothesis.
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In addition to the 5-HT3 receptor, other mechanisms may also contribute to the differential 
effects of EtOH. Evidence has shown that EtOH can directly activate VTA DA neurons 
(Brodie et al. 1999), which may be through the actions of EtOH on certain voltage 
dependent ion channels (Brodie and Appel 1998; Okamoto et al. 2006) and/or α4β2 
nicotinic receptors in VTA DA neurons (Narahashi et al. 1999). On the other hand, EtOH 
could indirectly stimulate DA neurons via suppression of GABA inter-neurons through 
either increasing opioid receptor neurotransmission to GABA inter-neurons (Johnson and 
North 1992) and/or decreasing NMDA receptor functions on these neurons (Stobbs et al. 
2004). It is possible that some or all of these mechanisms may exist in the pVTA but not in 
the aVTA, thus contributing to the differential effects of EtOH between these two sub-
regions. Further studies will be needed to address the mechanisms of differential effects of 
EtOH within the VTA.
In summary, the present study indicated that direct application of EtOH in the pVTA but not 
aVTA stimulates local mesopallidal and mesocortical DA neurons. These findings suggest 
that activation of these systems may be involved in mediating the local effects of EtOH. 
Furthermore, the stimulating effects of EtOH within the pVTA appeared to be mediated, at 
least in part, by activation of local 5-HT3 receptors, as indicated by the reduction of EtOH 
effects by co-infusions of the 5-HT3 receptor antagonist ICS-205,930.
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Figure 1. 
Photomicrographs (A & B) and schematic representation (C & D) of brain slices with 
microdialysis probes in the medial prefrontal cortex (mPFC, A & C) and ventral pallidum 
(VP, B & D). The arrow indicates the position of the probe. The lines represent the 2.0-mm 
length of microdialysis probes in the mPFC (C) and the 1.5-mm length of microdialysis 
probes in the VP (D).
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Figure 2. 
Photomicrographs (A & B) and schematic representation (C & D) of brain slices with 
injection sites within the anterior (A) and posterior (B) ventral tegmental area (VTA). The 
arrow indicates the tip of the micro-injector. The filled circles represent microinjection sites 
within the anterior VTA and the filled triangles represent microinjection sites within the 
posterior VTA, as defined by Rodd-Henricks et al (2000).
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Figure 3. 
Time-course effects of microinjections of EtOH (200 mg%; 44 mM) or aCSF in the 
posterior (A) or anterior (B) ventral tegmental area on extracellular dopamine levels in the 
ventral pallidum. * p < 0.05, significantly different from baselines and aCSF group.
Ding et al. Page 16
Psychopharmacology (Berl). Author manuscript; available in PMC 2015 September 09.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Figure 4. 
Effects of co-injections of the 5-HT3 receptor antagonist ICS-205,930 with EtOH (200 mg
%; 44 mM) in the posterior ventral tegmental area on EtOH-induced dopamine increase in 
the ventral pallidum (n = 5–8/group). ‘EtOH’ = ‘200 mg% EtOH’; ‘EtOH/100ICS’ = ‘200 
mg% EtOH + 100 μM ICS’; ‘EtOH/200ICS’ = ‘200 mg% EtOH + 200 μM ICS’; ‘200ICS = 
‘200 μM ICS’. * p < 0.05, significantly different from the ‘aCSF’ group; # p < 0.05, 
significantly different from the ‘EtOH’ group; $ p < 0.05, significantly different from the 
‘EtOH/100ICS’ group.
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Figure 5. 
Time-course effects of microinjections of EtOH (200 mg%; 44 mM) or aCSF in the 
posterior (A) or anterior (B) ventral tegmental area on extracellular dopamine levels in the 
medial prefrontal cortex. * p < 0.05, significantly different from baselines and aCSF group.
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Figure 6. 
Effects of co-injections of the 5-HT3 receptor antagonist ICS-205,930 with EtOH (200 mg
%; 44 mM) in the posterior ventral tegmental area on EtOH-induced dopamine increase in 
the medial prefrontal cortex (n = 4–8/group). ‘EtOH’ = ‘200 mg% EtOH’; ‘EtOH/100ICS’ = 
‘200 mg% EtOH + 100 μM ICS’; ‘EtOH/200ICS’ = ‘200 mg% EtOH + 200 μM ICS’; 
‘200ICS = ‘200 μM ICS’. * p < 0.05, significantly different from the ‘aCSF’ group; # p < 
0.05, significantly different from the ‘EtOH’ group.
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Figure 7. 
Effects of co-infusion of the GABAA receptor antagonist bicuculline with EtOH on self-
administration of 200 mg% EtOH into the posterior ventral tegmental area (VTA) of female 
Wistar rats. ‘aCSF’ = self-administration of aCSF in the posterior VTA (n = 4); ‘EtOH’ = 
self-administration of 200 mg% EtOH alone (n = 5); ‘EtOH/BIC’ = co-infusion of 200 mg% 
EtOH and 250 μM bicuculline (n = 5). Intracranial self-administration experiments were 
conducted as previously described (Rodd-Henricks et al. 2003). * p < 0.05, significantly 
higher responses on the active than inactive lever, and significantly higher responses on the 
active lever compared to responses by the ‘aCSF’ group. Responses on the active lever with 
200 mg% EtOH alone were not significantly different than responses with 200 mg% EtOH 
plus 250 μM bicuculline.
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Table 1
Basal extracellular dopamine levels in the ventral pallidum or the medial prefrontal cortex in each group of 
rats
Group Ventral Pallidum (nM) medial Prefrontal Cortex (nM)
Posterior VTA-aCSF 0.5 ± 0.1 0.2 ± 0.1
Anterior VTA-aCSF 0.7 ± 0.1 0.3 ± 0.1
Posterior VTA-200 mg% EtOH 0.4 ± 0.1 0.4 ± 0.1
Anterior VTA-200 mg% EtOH 0.9 ± 0.4 0.3 ± 0.1
200 mg% EtOH + 100 μM ICS 0.3 ± 0.1 0.2 ± 0.1
200 mg% EtOH + 200 μM ICS 0.3 ± 0.1 0.2 ± 0.1
200 μM ICS 0.3 ± 0.1 0.3 ± 0.1
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